← XBiotech Inc. (XBIT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
XBiotech Inc. (XBIT)
Pharmaceutical Preparations · market cap $66M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
XBiotech Inc. (XBIT) is a clinical-stage biopharmaceutical company based in Austin, Texas with 88 employees and a $71M market cap. Its lead asset, Natrunix, is in Phase 2 for Rheumatoid Arthritis, with a second asset, 514G3, in Phase 2 for Staphylococcus Aureus Bacteremia. The company holds $115.5M in cash — exceeding its market cap — providing approximately 38.6 months of runway against a burn rate of roughly $46-47M per year.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Natrunix | Phase 2 | Rheumatoid Arthritis |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment | Phase 2 | Staphylococcus Aureus Bacteremia |
| Phase I: XB2001 250 mg | Phase 2 | Pancreatic Cancer |
Price & technical context
3-month
-9.1%
6-month
-6.8%
12-month
-17.0%
52-wk range
$2.12–$2.94
vs 50-day MA
-2.2%
vs 200-day MA
-7.4%
Realized vol
43.4%
Max drawdown
-74.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for XBIT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.